# ENFLONSIA (clesrovimab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/clesrovimab

> The PDUFA target action date for ENFLONSIA (clesrovimab), sponsored by Merck & Co., Inc. (MRK), is March 22, 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the ENFLONSIA (clesrovimab) PDUFA date?

The PDUFA target action date for ENFLONSIA (clesrovimab), sponsored by Merck & Co., Inc. (MRK), is March 22, 2027. Status: scheduled. SEC Form 10-Q: "In the U.S., the FDA set a PDUFA date of March 22, 2027." Last confirmed November 4, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/clesrovimab)

Source: SEC Form 10-Q, accession 0000310158-26-000248, https://www.sec.gov/Archives/edgar/data/310158/000031015826000248/mrk-20260930.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/pdufa/clesrovimab#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | ENFLONSIA (clesrovimab) |
| Codes | MK-1654 |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications |  |
| Modality | antibody |
| FDA designations | none disclosed |

## Timeline

### June 10, 2025: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2025-02-25, last confirmed 2025-05-02.
- SEC Form 10-Q (accession 0001628280-25-021834): "In December 2024, the FDA accepted the BLA for clesrovimab and set a PDUFA date of June 10, 2025." https://www.sec.gov/Archives/edgar/data/310158/000162828025021834/mrk-20250331.htm
- SEC Form 10-K (accession 0001628280-25-007732): "In December 2024, the FDA accepted the BLA for clesrovimab and set a PDUFA date of June 10, 2025." https://www.sec.gov/Archives/edgar/data/310158/000162828025007732/mrk-20241231.htm

### March 22, 2027: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-10-29, last confirmed 2026-11-04.
- SEC Form 10-Q (accession 0000310158-26-000248): "In the U.S., the FDA set a PDUFA date of March 22, 2027." https://www.sec.gov/Archives/edgar/data/310158/000031015826000248/mrk-20260930.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-119825): "FDA set PDUFA date of March 22, 2027." https://www.sec.gov/Archives/edgar/data/310158/000110465926119825/tm2628203d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-119825): "RSV for Their Second Season; Based on Results From Phase 3 SMART Trial; FDA Set PDUFA Date of March 22, 2027" https://www.sec.gov/Archives/edgar/data/310158/000110465926119825/tm2628203d1_ex99-1.htm

Calendar months: [June 2025](https://sec-api.dev/fda-calendar/2025-06), [March 2027](https://sec-api.dev/fda-calendar/2027-03)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/clesrovimab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ENFLONSIA (clesrovimab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/clesrovimab

```bibtex
@misc{secapidev_pdufa_clesrovimab_20261116,
  title        = {ENFLONSIA (clesrovimab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/clesrovimab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_clesrovimab_20261116","title":"ENFLONSIA (clesrovimab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/clesrovimab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
